AAAText only | Accessibility | Privacy and cookies
Research
COVID-19
COVID-19 studies
RECOVERY trial
REMAP-CAP trial
COVID-19 information for researchers and sponsors
BRC Science Forum
 

About

Tom Wilkinson_457x220

ACCORD brings together doctors and scientists, industry and government to speed up the testing of drugs, with the aim of getting new COVID-19 treatments into national trials.

ACCORD has been made possible by partnership working between the Government Scientific Office, the NIHR’s Biomedical Research Centres and Clinical Research Facilities, and expert centres in Northern Ireland, Scotland and Wales, clinical research company IQVIA and biopharmaceutical company AstraZeneca.

Aim of the platform

ACCORD is a platform for multiple trials, which aims to assess several potential COVID-19 treatments at the same time.

These treatments are for those hospitalised with COVID-19 and will be given on top of standard care, compared with standard care alone.

Possible potential treatments include anti-viral drugs, drugs that affect the immune system and drugs which target inflammatory molecules.

What does it involve?

ACCORD has two stages:          

Stage 1: Evaluation/pilot – this initial stage will assess how well potential drugs work when added onto standard care, in small groups (10-50) of patients hospitalised with COVID‑19.

Stage 2: Confirmation – drugs that show the most potential will be assessed in larger numbers of patients hospitalised with COVID‑19.

At each stage patients will be assessed for their suitability to be involved either the day before starting the treatment or the first day of treatment. Treatment and assessments will continue for 29 days or until they are considered well enough to leave the hospital.  

They will also be asked to return for an appointment approximately 60 days after starting their treatment, with a final follow-up after approximately 90 days.

Who is leading it?

The ACCORD steering committee is chaired by Professor Tom Wilkinson, Professor of Respiratory Medicine at the University of Southampton and Honorary NHS Consultant Physician at University Hospital Southampton, and includes clinical experts, representatives of the trial sponsor and the UKRI, and representatives from the trial sites and delivery group.

×